Marius Ardeleanu
Regeneron (United States)(US)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Asthma and respiratory diseases, Allergic Rhinitis and Sensitization, Urticaria and Related Conditions, Food Allergy and Anaphylaxis Research
Most-Cited Works
- → Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis(2016)1,987 cited
- → Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis(2014)1,388 cited
- → Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis(2018)659 cited
- → Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial(2015)564 cited
- → Conjunctivitis in dupilumab clinical trials(2019)411 cited
- → Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis(2019)356 cited
- → Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults(2016)299 cited
- → Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study(2019)248 cited
- → A basophil-neuronal axis promotes itch(2021)247 cited
- → IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis(2019)208 cited